Chemomab Therapeutics (CMMB)

• Market cap: $13.6M
• 1 day: -6.43%
• 5 days: -12.67%
• 1 month: -30.32%
• 3 months: -45.42%
• 6 months: -56.33%
• Year to date: -69.25%
• 1 year: -63.41%
• 5 years: -96.14%
• 10 years: -99.62%
• Sector: Healthcare
• Industry: Biotechnology

About: Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Employees: 16

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

21% more capital invested

Capital invested by funds: $4.07M [Q1] → $4.91M (+$840K) [Q2]

5.36% more ownership

Funds ownership: 0.25% [Q1] → 5.61% (+5.36%) [Q2]

18% less funds holding

Funds holding: 17 [Q1] → 14 (-3) [Q2]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $25
• Avg. target: $25
• High target: $25

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Oppenheimer Jeff Jones

$25

Outperform Maintained

27 Aug 2025